{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T03:04:10Z","timestamp":1772679850663,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2016,10,29]],"date-time":"2016-10-29T00:00:00Z","timestamp":1477699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dentistry Journal"],"abstract":"<jats:p>Medication-induced Osteonecrosis of the Jaw (MRONJ) has been reported not only after use of antiresorptive agents (bisphosphonates and denosumab), but also in cancer patients receiving antiangiogenic agents, alone or combined with antiresorptive drugs. We report two cases of MRONJ observed in colorectal cancer patients after bevacizumab therapy only. MRONJ was diagnosed, respectively, two and seven months after a tooth extraction; both the patients had received two courses of bevacizumab infusions (for a total of 29 and 10 administrations, respectively). We discuss if tooth extraction during or after antiangiogenic therapy could be a potential trigger of MRONJ, but also if an underlying bone disease not evident before oral surgery might be a possible cause. A careful drug history has to be registered by dental specialists in cancer patients before oral surgery and adequate imaging might be obtained to avoid a delayed diagnosis.<\/jats:p>","DOI":"10.3390\/dj4040039","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T11:09:46Z","timestamp":1477912186000},"page":"39","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases"],"prefix":"10.3390","volume":"4","author":[{"given":"Francesco","family":"Erovigni","sequence":"first","affiliation":[{"name":"Oral Surgery Department, Dental School, AOUP Citt\u00e0 della Salute e della Scienza di Torino, Torino 10100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-0799","authenticated-orcid":false,"given":"Alessio","family":"Gambino","sequence":"additional","affiliation":[{"name":"Oral Surgery Department, Dental School, AOUP Citt\u00e0 della Salute e della Scienza di Torino, Torino 10100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Cabras","sequence":"additional","affiliation":[{"name":"Oral Surgery Department, Dental School, AOUP Citt\u00e0 della Salute e della Scienza di Torino, Torino 10100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Fasciolo","sequence":"additional","affiliation":[{"name":"Maxillofacial Unit, Alessandria Hospital, Alessandria 15121, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Radiology Department, Dental School, AOUP Citt\u00e0 della Salute e della Scienza di Torino, Torino 10100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Bellini","sequence":"additional","affiliation":[{"name":"Oncology Unit, Molinette Hospital, AOUP Citt\u00e0 della Salute e della Scienza di Torino, Torino 10100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Fusco","sequence":"additional","affiliation":[{"name":"Oncology Unit, Alessandria Hospital, Alessandria 15121, Italy"},{"name":"Centro di Documentazione Osteonecrosi, Alessandria 15121, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.joms.2008.10.005","article-title":"Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Initial discovery and subsequent development","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007). American association of oral and maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg., 65, 369\u2013376.","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","article-title":"American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: The need to refine the BRONJ definition","volume":"67","author":"Colella","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1601-0825.2012.01903.x","article-title":"Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"18","author":"Bedogni","year":"2012","journal-title":"Oral Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jbmr.2525","article-title":"Comments on \u201cdiagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus\u201d","volume":"30","author":"Otto","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_7","first-page":"c85","article-title":"Physiology and Pharmacology of Nonbisphosphonate Drugs Implicated in Osteonecrosis of the Jaw","volume":"78","author":"Troeltzsch","year":"2012","journal-title":"J. Can. Dent. Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","article-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: New horizons in oncology","volume":"15","author":"Fusco","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/039463200902200429","article-title":"Bevacizumab-related osteonecrosis of the jaw","volume":"22","author":"Serra","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"687043","DOI":"10.1155\/2010\/687043","article-title":"Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: A case series and review of the literature","volume":"2010","author":"Agostino","year":"2010","journal-title":"Adv. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bettini, G., Blandamura, S., Saia, G., and Bedogni, A. (2012). Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep.","DOI":"10.1136\/bcr-2012-007284"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/039463201202500328","article-title":"Osteonecrosis of the jaws and bevacizumab therapy: A case report","volume":"25","author":"Bandelloni","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","article-title":"Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab","volume":"17","author":"Pakosch","year":"2013","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Dias","year":"2013","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ors.12153","article-title":"Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing anti-angiogenic therapy with bevacizumab","volume":"9","author":"Tzermpos","year":"2016","journal-title":"Oral Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit","volume":"48","author":"Er","year":"2012","journal-title":"Oral Oncol."},{"key":"ref_20","first-page":"655","article-title":"A case of osteonecrosis of the jaw during treatment by bevacizumab for sigmoid colon cancer","volume":"110","author":"Sato","year":"2013","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"vi164","DOI":"10.1093\/annonc\/mdm249","article-title":"New developments of aminobisphosphonates: The double face of Janus","volume":"18","author":"Santini","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1756-8722-5-56","article-title":"Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw","volume":"5","author":"Vincenzi","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1600-0714.2010.01004.x","article-title":"Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws","volume":"40","author":"Arduino","year":"2011","journal-title":"J. Oral Pathol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1601-0825.2010.01720.x","article-title":"Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro","volume":"17","author":"Walter","year":"2011","journal-title":"Oral Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2014A review","volume":"48","author":"Walter","year":"2012","journal-title":"Oral Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon.13.211","article-title":"Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents","volume":"10","author":"Campisi","year":"2014","journal-title":"Future Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00784-013-1060-x","article-title":"Bisphosphonates\u2019 antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: Influence on microvessel sprouting in an in vivo 3D Matrigel assay","volume":"18","author":"Pabst","year":"2014","journal-title":"Clin. Oral Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ponzetti, A., Pinta, F., Spadi, R., Mecca, C., Fanchini, L., Zanini, M., Ciuffreda, L., and Racca, P. (2015). Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: Attention to oral district. Tumori.","DOI":"10.5301\/tj.5000405"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Antonuzzo, L., Lunghi, A., Giommoni, E., Brugia, M., and Di Costanzo, F. (2016). Regorafenib Also Can Cause Osteonecrosis of the Jaw. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djw002"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fusco, V., Campisi, G., Numico, G., Migliorati, C.A., Santini, D., and Bedogni, A. (2016). RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djw155"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2008.05.015","article-title":"Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer","volume":"63","author":"Renk","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing. An important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann. Plast. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J. Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","article-title":"Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts","volume":"473","author":"Nakagawa","year":"2000","journal-title":"FEBS Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.oooo.2015.08.007","article-title":"Periodontaldiseaseprecedingosteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: Report of 5 cases and literature review","volume":"120","author":"Razis","year":"2015","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.clon.2011.03.009","article-title":"Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer","volume":"23","author":"Garant","year":"2011","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_42","unstructured":"(2011). Bevacizumab, sunitinib: Osteonecrosis of the jaw. Prescrire Int., 20, 155."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejso.2011.06.004","article-title":"Review: Incidence and clinical significance of bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer","volume":"37","author":"Hompes","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_44","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bjoms.2014.04.009","article-title":"Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease","volume":"52","author":"Bedogni","year":"2014","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bjoms.2014.09.001","article-title":"Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed","volume":"53","author":"Fedele","year":"2015","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00784-015-1563-8","article-title":"Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"20","author":"Thomas","year":"2016","journal-title":"Clin. Oral Investig."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fusco, V., Bedogni, A., Addeo, A., and Campisi, G. (2016). Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: Supplementary data from the denosumab extension study?. Support. Care Cancer.","DOI":"10.1007\/s00520-016-3147-9"}],"container-title":["Dentistry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2304-6767\/4\/4\/39\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:34:17Z","timestamp":1760211257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2304-6767\/4\/4\/39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,29]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["dj4040039"],"URL":"https:\/\/doi.org\/10.3390\/dj4040039","relation":{},"ISSN":["2304-6767"],"issn-type":[{"value":"2304-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,29]]}}}